Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer

(MedPage Today) -- PARIS--A novel combination failed to improve the clinical benefit rate (CBR) in advanced triple-negative breast cancer (TNBC) compared with chemoimmunotherapy, a randomized trial showed.
Adding the anti-CD73 antibody oleclumab...